Daniel Mertens
Overview
Explore the profile of Daniel Mertens including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
94
Citations
3120
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yosifov D, Reichenzeller M, Stilgenbauer S, Mertens D
BMC Bioinformatics
. 2024 Oct;
25(1):331.
PMID: 39407133
Background: The dilution-replicate experimental design for qPCR assays is especially efficient. It is based on multiple linear regression of multiple 3-point standard curves that are derived from the experimental samples...
2.
Ehrmann A, Zadro A, Tausch E, Schneider C, Stilgenbauer S, Mertens D
Leuk Lymphoma
. 2024 Aug;
65(13):1941-1953.
PMID: 39161195
In chronic lymphocytic leukemia (CLL), mutations or deletions on chromosome 17p lead to adverse prognosis and reduced levels of miR-34a, which targets NOTCH1. Also, hyperactivated NOTCH1 signaling is crucial for...
3.
Schmutz M, Zucknick M, Schlenk R, Mertens D, Benner A, Weichenhan D, et al.
Clin Epigenetics
. 2023 Oct;
15(1):171.
PMID: 37885041
Background: Acute myeloid leukemia (AML) is a heterogeneous disease with a poor prognosis. Dysregulation of the epigenetic machinery is a significant contributor to disease development. Some AML patients benefit from...
4.
Piroeva K, McDonald C, Xanthopoulos C, Fox C, Clarkson C, Mallm J, et al.
Genome Res
. 2023 Sep;
33(10):1649-1661.
PMID: 37699659
The location of nucleosomes in the human genome determines the primary chromatin structure and regulates access to regulatory regions. However, genome-wide information on deregulated nucleosome occupancy and its implications in...
5.
Qi J, Endres S, Yosifov D, Tausch E, Dheenadayalan R, Gao X, et al.
Blood Adv
. 2023 Jan;
7(19):5698-5702.
PMID: 36661329
No abstract available.
6.
Urbanek K, Stilgenbauer S, Mertens D
Cancers (Basel)
. 2023 Jan;
15(1).
PMID: 36612190
WNT pathways play an important role in cancer development and progression, but WNT pathways can also inhibit growth in melanoma, prostate, and ovarian cancers. Chronic lymphocytic leukemia (CLL) is known...
7.
Baumgartner M, Zirnbauer R, Schlager S, Mertens D, Gasche N, Sladek B, et al.
Gut Microbes
. 2022 Nov;
14(1):2143218.
PMID: 36415023
With increasing urbanization and industrialization, the prevalence of inflammatory bowel diseases (IBDs) has steadily been rising over the past two decades. IBD involves flares of gastrointestinal (GI) inflammation accompanied by...
8.
Ferrante F, Giaimo B, Friedrich T, Sugino T, Mertens D, Kugler S, et al.
Cell Death Dis
. 2022 Jul;
13(7):600.
PMID: 35821235
Notch signaling plays a pivotal role in the development and, when dysregulated, it contributes to tumorigenesis. The amplitude and duration of the Notch response depend on the posttranslational modifications (PTMs)...
9.
Wolf C, Maus C, Persicke M, Filarsky K, Tausch E, Schneider C, et al.
Int J Cancer
. 2022 May;
151(5):783-796.
PMID: 35527719
B-cell receptor (BCR) signaling is central for the pathomechanism of chronic lymphocytic leukemia (CLL), and inhibitors of BCR signaling have substantially improved treatment options. To model malignant and nonmalignant BCR...
10.
Jebaraj B, Muller A, Dheenadayalan R, Endres S, Roessner P, Seyfried F, et al.
Blood
. 2021 Oct;
139(6):859-875.
PMID: 34662393
Covalent Bruton tyrosine kinase (BTK) inhibitors, such as ibrutinib, have proven to be highly beneficial in the treatment of chronic lymphocytic leukemia (CLL). Interestingly, the off-target inhibition of IL-2-inducible T-cell...